LifeMD price target raised to $15 from $12 at BTIG

BTIG raised the firm’s price target on LifeMD (LFMD) to $15 from $12 and keeps a Buy rating on the shares as part of a broader research note in summary of presentations at the recent Boston Digital Health Summit. The firm believe that nearly all companies in its coverage group can and will benefit from AI, though the direct-to-consumer solutions like LifeMD and Hims (HIMS) may be able to drive more value quickly given the relatively high number of engagements with members, especially with respect to obesity health, the analyst tells investors in a research note.